(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Suicidal ideation and behavior are among the most severe psychiatric presentations, warranting emergency room visits and psychiatric admission for higher levels of care. In the United States, suicide rates continue to climb, especially in younger patients, and the continued psychosocial stressors of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Chronic Stress |
| Online Access: | https://doi.org/10.1177/24705470221128017 |
| _version_ | 1798027678505238528 |
|---|---|
| author | Alexandra A. Alario Mark J. Niciu |
| author_facet | Alexandra A. Alario Mark J. Niciu |
| author_sort | Alexandra A. Alario |
| collection | DOAJ |
| description | Suicidal ideation and behavior are among the most severe psychiatric presentations, warranting emergency room visits and psychiatric admission for higher levels of care. In the United States, suicide rates continue to climb, especially in younger patients, and the continued psychosocial stressors of the COVID-19 pandemic may further exacerbate this crisis. Suicidal ideation and behavior are core features of a major depressive episode, but there are limited treatment options to rapidly redress these life-threatening symptoms. Racemic ketamine and its S-enantiomer, esketamine, are N-methyl-D-aspartate receptor antagonists and glutamate modulators that have robust antidepressant efficacy in treatment-resistant major depressive disorder and bipolar depression. Additionally, both ketamine and esketamine have demonstrated rapid-acting antisuicidal efficacy in major mood disorders. In August 2020, this culminated in a first-in-class approval of Spravato® (intranasal esketamine) for the treatment of major depressive disorder with acute suicidal ideation and behavior. In this article, we review the literature in support of the antisuicidal efficacy of ketamine and esketamine. |
| first_indexed | 2024-04-11T18:55:32Z |
| format | Article |
| id | doaj.art-ad988c4069214617aa2ef0af84fd80e1 |
| institution | Directory Open Access Journal |
| issn | 2470-5470 |
| language | English |
| last_indexed | 2024-04-11T18:55:32Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Chronic Stress |
| spelling | doaj.art-ad988c4069214617aa2ef0af84fd80e12022-12-22T04:08:11ZengSAGE PublishingChronic Stress2470-54702022-10-01610.1177/24705470221128017(Es)Ketamine for Suicidal Ideation and Behavior: Clinical EfficacyAlexandra A. AlarioMark J. NiciuSuicidal ideation and behavior are among the most severe psychiatric presentations, warranting emergency room visits and psychiatric admission for higher levels of care. In the United States, suicide rates continue to climb, especially in younger patients, and the continued psychosocial stressors of the COVID-19 pandemic may further exacerbate this crisis. Suicidal ideation and behavior are core features of a major depressive episode, but there are limited treatment options to rapidly redress these life-threatening symptoms. Racemic ketamine and its S-enantiomer, esketamine, are N-methyl-D-aspartate receptor antagonists and glutamate modulators that have robust antidepressant efficacy in treatment-resistant major depressive disorder and bipolar depression. Additionally, both ketamine and esketamine have demonstrated rapid-acting antisuicidal efficacy in major mood disorders. In August 2020, this culminated in a first-in-class approval of Spravato® (intranasal esketamine) for the treatment of major depressive disorder with acute suicidal ideation and behavior. In this article, we review the literature in support of the antisuicidal efficacy of ketamine and esketamine.https://doi.org/10.1177/24705470221128017 |
| spellingShingle | Alexandra A. Alario Mark J. Niciu (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy Chronic Stress |
| title | (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy |
| title_full | (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy |
| title_fullStr | (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy |
| title_full_unstemmed | (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy |
| title_short | (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy |
| title_sort | es ketamine for suicidal ideation and behavior clinical efficacy |
| url | https://doi.org/10.1177/24705470221128017 |
| work_keys_str_mv | AT alexandraaalario esketamineforsuicidalideationandbehaviorclinicalefficacy AT markjniciu esketamineforsuicidalideationandbehaviorclinicalefficacy |